Novartis AG (NVS) shared some encouraging news Friday about Vanrafia, its kidney disease drug that's been operating under conditional approval. The final Phase 3 ALIGN study results suggest the drug actually helps slow the progression of IgA nephropathy, a chronic autoimmune kidney disease that gradually destroys kidney function.

Here's what makes this matter: IgA nephropathy (also called Berger's disease) happens when immunoglobulin A protein builds up in the glomeruli, the kidney's tiny filtering units. This buildup causes inflammation and progressively damages the kidneys' ability to filter waste from the blood. It's a slow-motion disease that can eventually lead to kidney failure.

Vanrafia received accelerated approval in both the U.S. and China back in April 2025 for reducing proteinuria (excess protein in urine) in adults with IgAN. But here's the catch with accelerated approvals: they come with homework. The FDA basically said "this looks promising, but prove it actually slows disease progression or we'll reconsider." That's where the ALIGN study comes in.

The Numbers That Matter

The study measured estimated glomerular filtration rate (eGFR), which is essentially how well your kidneys are filtering. At week 136, four weeks after patients stopped taking the drug, Vanrafia showed a difference of 2.39 ml/min/1.73m2 compared to placebo. The statistical significance just missed the traditional threshold (p = 0.057), but clinically meaningful results showed up elsewhere.

At week 132, right at the end of treatment, the difference was even better at 2.59 ml/min/1.73 m2. And in patients who were also taking SGLT2 inhibitors (another class of drugs often used in kidney disease), the results were particularly strong.

Novartis emphasized Friday that ALIGN represents the longest follow-up period in any pivotal Phase 3 study for IgAN, and the safety profile matched what they'd seen in earlier trials. Armed with this data, the company plans to submit for traditional FDA approval in 2026.

Vanrafia isn't Novartis''s only play in this space. The company is building out a multi-drug IgAN portfolio that includes Fabhalta (iptacopan) and an investigational compound called zigakibart. It's a smart strategy for a disease that likely won't have a one-size-fits-all solution.

Stock Movement: Novartis (NVS) shares rose 0.42% to $161.86 in premarket trading Friday, hovering near the 52-week high of $162.31.